1Bowen, JM, Gibson, RJ, Cummins, AG, et al. (2006) Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 14, 713–731.
2Gibson, RJ, Bowen, JM & Keefe, DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116, 464–470.
3Lalla, RV & Peterson, DE (2006) Treatment of mucositis, including new medications. Cancer J 12, 348–354.
4Choi, K, Lee, SS, Oh, SJ, et al. (2007) The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr 26, 57–62.
5Keefe, DM (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12, 6–9.
6Logan, RM, Stringer, AM, Bowen, JM, et al. (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33, 448–460.
7Keefe, DM, Gibson, RJ & Hauer-Jensen, M (2004) Gastrointestinal mucositis. Semin Oncol Nurs 20, 38–47.
8Gibson, RJ, Keefe, DMK, Clarke, JM, et al. (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50, 53–58.
9von Bultzingslowen, I, Brennan, MT, Spijkervet, FK, et al. (2006) Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 14, 519–527.
10Cool, JC, Dyer, JL, Xian, CJ, et al. (2005) Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 15, 72–82.
11Howarth, GS (2003) Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J Nutr 133, 2109–2112.
12Howarth, GS, Francis, GL, Cool, JC, et al. (1996) Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 126, 2519–2530.
13Clarke, J, Butler, RN, Howarth, GS, et al. (2002) Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 38, 478–485.
14Gibson, RJ, Stringer, AM, Bowen, JM, et al. (2007) Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 6, 541–547.
15Whitehouse, MW, Turner, AG, Davis, CK, et al. (1998) Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine. Inflammopharmacology 6, 1–8.
16Beckerbauer, LM, Thiel-Cooper, R, Ahn, DU, et al. (2001) Influence of two dietary fats on the composition of emu oil and meat. Poult Sci 80, 187–194.
17Yoganathan, S, Nicolosi, R, Wilson, T, et al. (2003) Antagonism of croton oil inflammation by topical emu oil in CD-1 mice. Lipids 38, 603–607.
18Lopez, A, Sims, DE, Ablett, RF, et al. (1999) Effect of emu oil on auricular inflammation induced with croton oil in mice. Am J Vet Res 60, 1558–1561.
19Snowden, JM & Whitehouse, MW (1997) Anti-inflammatory activity of emu oils in rats. Inflammopharmacology 5, 127–132.
20Qiu, XW, Wang, JH, Fang, XW, et al. (2005) Anti-inflammatory activity and healing-promoting effects of topical application of emu oil on wound in scalded rats. Di Yi Jun Yi Da Xue Xue Bao 25, 407–410.
21Tomas, FM, Murray, AJ & Jones, LM (1984) Modification of glucocorticoid-induced changes in myofibrillar protein turnover in rats by protein and energy deficiency as assessed by urinary excretion of Ntau-methylhistidine. Br J Nutr 51, 323–337.
22Pelton, NS, Tivey, DR, Howarth, GS, et al. (2004) A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 39, 2.
23Tooley, KL, Howarth, GS, Lymn, KA, et al. (2009) Optimization of the non-invasive 13C-sucrose breath test in a rat model of methotrexate-induced mucositis. Cancer Chemother Pharmacol 65, 913–921.
24Cheng, H & Bjerknes, M (1982) Whole population cell kinetics of mouse duodenal, jejunal, ileal, and colonic epithelia as determined by radioautography and flow cytometry. Anat Rec. 203, 251–264.
25Singh, U & Jialal, I (2004) Anti-inflammatory effects of alpha-tocopherol. Ann N Y Acad Sci 1031, 195–203.
26Sylvester, PW (2007) Vitamin E and apoptosis. Vitam Horm 76, 329–356.
27Bennett, DC, Code, WE, Godin, DV, et al. (2008) Comparison of the antioxidant properties of emu oil with other avian oils. Anim Prod Sci 48, 1345–1350.
28Sonis, ST (2004) Pathobiology of mucositis. Semin Oncol Nurs 20, 11–15.
29Sonis, ST, Elting, LS, Keefe, D, et al. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100, 1995–2025.
30Drozdowski, L & Thomson, ABR (2006) Intestinal mucosal adaptation. World J Gastroenterol 12, 4614–4627.
31Haxhija, EQ, Yang, H, Spencer, AU, et al. (2007) Intestinal epithelial cell proliferation is dependent on the site of massive small bowel resection. Paediatric Surg Int 23, 379–390.
32Torres, DM, Tooley, KL, Butler, RN, et al. (2008) Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. Cancer Biol Ther 7, 295–302.